Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07364058

Assessment of Platelet-derived GARP in Atherosclerotic Disease

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Université Catholique de Louvain · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Conditions

Interventions

TypeNameDescription
OTHERTissue sample and data collectionTissue sample and data collection

Timeline

Start date
2026-02-01
Primary completion
2029-01-01
Completion
2029-01-01
First posted
2026-01-23
Last updated
2026-01-27

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT07364058. Inclusion in this directory is not an endorsement.